Literature DB >> 12683404

Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.

Helen Donners1, David Davis, Betty Willems, Guido van der Groen.   

Abstract

HIV-1 infected individuals with cross-neutralizing antibodies against primary HIV-1 isolates belonging to Group M (envA-H) and O, are identified. To investigate the neutralization-kinetics of primary isolates with these antibodies, different neutralization assay conditions are compared. Each set is summarized as a/b/c where a is the time in hours for which antibody is incubated with virus, b is the time in hours allowed for virus to absorb to cells, c is the total culture period in days, from the cells' first exposure to virus, before antigen production (peripheral blood mononuclear cells) or number of fluorescent cells (GHOST) are measured. In HIV-infected individuals, neutralizing antibodies can be detected against a wide range of primary isolates (Group M; A-H and Group O) in PBMC-assays with short incubation phases (1/2/7 or 1/24/7). If cultures are extended (1/2/14 or 1/24/14), however, neutralization can be lost. In kinetic experiments, neutralization can even be seen without pre-incubation (a=0 hr). This study shows that neutralization of primary HIV isolates by cross-reactive antibodies can continue after the virus has bound to its target cell. This neutralization, however, is not an all or nothing loss in virus infectivity. Most often it leads only to a reduction in viral replication rates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12683404     DOI: 10.1002/jmv.10288

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility.

Authors:  Kurt Vermeire; Kristel Van Laethem; Wouter Janssens; Thomas W Bell; Dominique Schols
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

2.  Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies.

Authors:  David Davis; Wim Koornstra; Daniella Mortier; Zahra Fagrouch; Ernst J Verschoor; Jonathan L Heeney; Willy M J M Bogers
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

3.  In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.

Authors:  David Davis; Wim Koornstra; Zahra Fagrouch; Ernst J Verschoor; Jonathan L Heeney; Willy M J M Bogers
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.